Recently, a small-molecule inhibitor of BET bromodomains, JQ1, with high affinity for the first bromodomain of Brd4, has received much attention for its therapeutic potential against multiple myeloma and other cancer types that are addicted to the c-Myc oncogene [44-46]. This evidence concerns the gene DNER and plasma cell myeloma.